1 |
Liang, J., Ge, F., Guo, C., Luo, G., Wang, X., Han, G., Zhang, D., Wang, J., Li, K., Pan, Y., Yao, L., Yin, Z., Guo, X., Wu, K., Ding, J. and Fan, D. (2009) Inhibition of PI3K/Akt partially leads to the inhibition of -induced drug resistance in gastric cancer cells. FEBS J. 276, 685-694.
DOI
|
2 |
Liang, J. and Kong, Q. (2012) -Cleavage of cellular prion protein. Prion 6, 453-460.
DOI
|
3 |
Liang, J., Pan, Y., Zhang, D., Guo, C., Shi, Y., Wang, J., Chen, Y., Wang, X., Liu, J., Guo, X., Chen, Z., Qiao, T. and Fan, D. (2007) Cellular prion protein promotes proliferation and G1/S transition of human gastric cancer cells SGC7901 and AGS. FASEB J. 21, 2247-2256.
DOI
|
4 |
Liu, L. Z., Zhou, X. D., Qian, G., Shi, X., Fang, J. and Jiang, B. H. (2007) AKT1 amplification regulates cisplatin resistance in human lung cancer cells through the mammalian target of rapamycin/ p70S6K1 pathway. Cancer Res. 67, 6325-6332.
DOI
|
5 |
Longley, D. B., Harkin, D. P. and Johnston, P. G. (2003) 5-fluorouracil: mechanisms of action and clinical strategies. Nat. Rev. Cancer 3, 330-338.
DOI
|
6 |
Luo, J., Manning, B. D. and Cantley, L. C. (2003) Targeting the PI3KAkt pathway in human cancer: rationale and promise. Cancer Cell 4, 257-262.
DOI
|
7 |
Malaga-Trillo, E., Solis, G. P., Schrock, Y., Geiss, C., Luncz, L., Thomanetz, V. and Stuermer, C. A. (2009) Regulation of embryonic cell adhesion by the prion protein. PLoS Biol. 7, e55.
|
8 |
Manning, B. D. and Cantley, L. C. (2007) AKT/PKB signaling: navigating downstream. Cell 129, 1261-1274.
DOI
|
9 |
Martin-Lanneree, S., Hirsch, T. Z., Hernandez-Rapp, J., Halliez, S., Vilotte, J. L., Launay, J. M. and Mouillet-Richard, S. (2014) PrPC from stem cells to cancer. Front Cell Dev Biol 2, 55.
|
10 |
Tsukuda, M., Ishitoya, J., Matsuda, H., Horiuchi, C., Taguchi, T., Takahashi, M., Nishimura, G., Kawakami, M., Watanabe, M., Niho, T., Kawano, T., Ikeda, Y., Sakuma, Y., Shiono, O. and Komatsu, M. (2010) Randomized controlled phase II comparison study of concurrent chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil versus CCRT with cisplatin, 5-fluorouracil, methotrexate and leucovorin in patients with locally advanced squamous cell carcinoma of the head and neck. Cancer Chemother. Pharmacol. 66, 729-736.
DOI
|
11 |
Vanhaesebroeck, B., Guillermet-Guibert, J., Graupera, M. and Bilanges, B. (2010) The emerging mechanisms of isoform-specific PI3K signalling. Nat. Rev. Mol. Cell Biol. 11, 329-341.
|
12 |
Vassallo, N., Herms, J., Behrens, C., Krebs, B., Saeki, K., Onodera, T., Windl, O. and Kretzschmar, H. A. (2005) Activation of phosphatidylinositol 3-kinase by cellular prion protein and its role in cell survival. Biochem. Biophys. Res. Commun. 332, 75-82.
DOI
|
13 |
Wang, J. H., Du, J. P., Zhang, Y. H., Zhao, X. J., Fan, R. Y., Wang, Z. H., Wu, Z. T. and Han, Y. (2011) Dynamic changes and surveillance function of prion protein expression in gastric cancer drug resistance. World J. Gastroenterol. 17, 3986-3993.
DOI
|
14 |
Yuan, T. L. and Cantley, L. C. (2008) PI3K pathway alterations in cancer: variations on a theme. Oncogene 27, 5497-5510.
DOI
|
15 |
Adelstein, D. J., Saxton, J. P., Rybicki, L. A., Esclamado, R. M., Wood, B. G., Strome, M., Lavertu, P., Lorenz, R. R. and Carroll, M. A. (2006) Multiagent concurrent chemoradiotherapy for locoregionally advanced squamous cell head and neck cancer: mature results from a single institution. J. Clin. Oncol. 24, 1064-1071.
DOI
|
16 |
Alvarez, P., Marchal, J. A., Boulaiz, H., Carrillo, E., Velez, C., Rodriguez- Serrano, F., Melguizo, C., Prados, J., Madeddu, R. and Aranega, A. (2012) 5-Fluorouracil derivatives: a patent review. Expert Opin. Ther. Pat. 22, 107-123.
DOI
|
17 |
Wang, Q., Qian, J., Wang, F. and Ma, Z. (2012) Cellular prion protein accelerates colorectal cancer metastasis via the Fyn-SP1-SATB1 axis. Oncol. Rep. 28, 2029-2034.
DOI
|
18 |
Weise, J., Sandau, R., Schwarting, S., Crome, O., Wrede, A., Schulz- Schaeffer, W., Zerr, I. and Bahr, M. (2006) Deletion of cellular prion protein results in reduced Akt activation, enhanced postischemic caspase-3 activation, and exacerbation of ischemic brain injury. Stroke 37, 1296-1300.
DOI
|
19 |
Yang, X., Zhang, Y., Zhang, L., He, T., Zhang, J. and Li, C. (2014) Prion protein and cancers. Acta Biochim. Biophys. Sin. (Shanghai) 46, 431-440.
DOI
|
20 |
Brown, D. R., Schulz-Schaeffer, W. J., Schmidt, B. and Kretzschmar, H. A. (1997) Prion protein-deficient cells show altered response to oxidative stress due to decreased SOD-1 activity. Exp. Neurol. 146, 104-112.
DOI
|
21 |
Cheng, Y., Tao, L., Xu, J., Li, Q., Yu, J., Jin, Y., Chen, Q., Xu, Z., Zou, Q. and Liu, X. (2014) CD44/cellular prion protein interact in multidrug resistant breast cancer cells and correlate with responses to neoadjuvant chemotherapy in breast cancer patients. Mol. Carcinog. 53, 686-697.
DOI
|
22 |
Du, L., Rao, G., Wang, H., Li, B., Tian, W., Cui, J., He, L., Laffin, B., Tian, X., Hao, C., Liu, H., Sun, X., Zhu, Y., Tang, D. G., Mehrpour, M., Lu, Y. and Chen, Q. (2013) CD44-positive cancer stem cells expressing cellular prion protein contribute to metastatic capacity in colorectal cancer. Cancer Res. 73, 2682-2694.
DOI
|
23 |
Hammond, W. A., Swaika, A. and Mody, K. (2016) Pharmacologic resistance in colorectal cancer: a review. Ther. Adv. Med. Oncol. 8, 57-84.
DOI
|
24 |
Holohan, C., Van Schaeybroeck, S., Longley, D. B. and Johnston, P. G. (2013) Cancer drug resistance: an evolving paradigm. Nat. Rev. Cancer 13, 714-726.
DOI
|
25 |
Li, Q. Q., Sun, Y. P., Ruan, C. P., Xu, X. Y., Ge, J. H., He, J., Xu, Z. D., Wang, Q. and Gao, W. C. (2011) Cellular prion protein promotes glucose uptake through the Fyn-HIF-2 -Glut1 pathway to support colorectal cancer cell survival. Cancer Sci. 102, 400-406.
DOI
|
26 |
Oliphant, R., Nicholson, G. A., Horgan, P. G., Molloy, R. G., McMillan, D. C. and Morrison, D. S. (2013) Deprivation and colorectal cancer surgery: longer-term survival inequalities are due to differential postoperative mortality between socioeconomic groups. Ann. Surg. Oncol. 20, 2132-2139.
DOI
|
27 |
McEwan, J. F., Windsor, M. L. and Cullis-Hill, S. D. (2009) Antibodies to prion protein inhibit human colon cancer cell growth. Tumour Biol. 30, 141-147.
DOI
|
28 |
McLennan, N. F., Brennan, P. M., McNeill, A., Davies, I., Fotheringham, A., Rennison, K. A., Ritchie, D., Brannan, F., Head, M. W., Ironside, J. W., Williams, A. and Bell, J. E. (2004) Prion protein accumulation and neuroprotection in hypoxic brain damage. Am. J. Pathol. 165, 227-235.
DOI
|
29 |
Mehrpour, M. and Codogno, P. (2010) Prion protein: From physiology to cancer biology. Cancer Lett. 290, 1-23.
DOI
|
30 |
Park, J. Y., Jeong, J. K., Lee, J. H., Moon, J. H., Kim, S. W., Lee, Y. J. and Park, S. Y. (2015) Induction of cellular prion protein (PrPC) under hypoxia inhibits apoptosis caused by TRAIL treatment. Oncotarget 6, 5342-5353.
|
31 |
Zhang, N., Yin, Y., Xu, S. J. and Chen, W. S. (2008) 5-Fluorouracil: mechanisms of resistance and reversal strategies. Molecules 13, 1551-1569.
DOI
|
32 |
Pignon, J. P., Bourhis, J., Domenge, C. and Designe, L. (2000) Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet 355, 949-955.
DOI
|
33 |
Siegel, R. L., Miller, K. D. and Jemal, A. (2017) Cancer Statistics, 2017. CA Cancer J. Clin. 67, 7-30.
DOI
|
34 |
Yun, C. W., Yun, S., Lee, J. H., Han, Y. S., Yoon, Y. M., An, D. and Lee, S. H. (2016) Silencing Prion Protein in HT29 Human Colorectal Cancer Cells Enhances Anticancer Response to Fucoidan. Anticancer Res. 36, 4449-4458.
DOI
|